SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,472

Sector

Pharmaceuticals

Calendar

03-27 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
26-02-06	10.72 ¥	+0.47%	12,926,310
26-02-05	10.67 ¥	+0.28%	8,325,334
26-02-04	10.64 ¥	+1.14%	8,968,839
26-02-03	10.52 ¥	+0.77%	7,717,648
26-02-02	10.44 ¥	-1.79%	10,653,620

End-of-day quote Shanghai S.E., February 05, 2026

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2026-02-06			5-day change	1st Jan Change
10.72 ^CNY	+0.47%		+0.85%	+6.14%

01-27	Shanghai Shyndec Pharmaceutical's Attributable Profit Slides 13%	MT
01-26	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Capitalization	13.55B 1.95B 1.65B 1.51B 1.43B 2.66B 177B 2.78B 17.6B 6.97B 85.14B 7.32B 7.17B 306B	P/E ratio 2023	18x	P/E ratio 2024	14.8x
Enterprise value	7.04B 1.01B 859M 787M 746M 1.38B 91.93B 1.45B 9.15B 3.62B 44.25B 3.81B 3.73B 159B	EV / Sales 2023	0.69x	EV / Sales 2024	0.87x
Free-Float	41.74%	Yield 2023	1.02%	Yield 2024	2.51%

01-27	Shanghai Shyndec Pharmaceutical's Attributable Profit Slides 13%	MT
01-26	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
12-26	Shyndec Pharmaceutical Gets China Nod for Antipsychotic	MT
12-12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
12-01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
11-04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
25-10-29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
25-10-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
25-10-13	Shyndec Pharmaceutical's Unit Gets Nod to Market Sitagliptin Phosphate	MT
25-09-23	Shyndec Pharmaceutical's Subsidiary Gets Nod to Add Specification to Vitamin B6 Injection	MT
25-09-18	Shyndec Pharma's Enalapril Maleate Tablets Passes Regulator's Consistency Evaluation	MT

1 day	+0.47%
1 week	+0.85%
Current month	+0.85%
1 month	+3.78%
3 months	+2.88%
6 months	-4.88%
Current year	+6.14%

Shanghai Shyndec Pharmaceutical Co., Ltd. Stock

Equities

600420

CNE000001JG2

Pharmaceuticals

Valuation: Shanghai Shyndec Pharmaceutical Co., Ltd.

Chart: Shanghai Shyndec Pharmaceutical Co., Ltd.

Latest news: Shanghai Shyndec Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shanghai Shyndec Pharmaceutical Co., Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 week	10.43	10.88
1 month	10.37	10.88
Current year	10.1	10.88
1 year	9.69	11.89
3 years	7.61	14.41
5 years	7.61	14.41
10 years	7.61	18.5

Manager	Title	Age	Since
Jing Zu DFI	Director of Finance/CFO	56	-
Qian Yin Jing IRC	Investor Relations Contact	46	2019-09-12
Zhong Xi Zhang SEC	Corporate Secretary	50	2024-03-27

Director	Title	Age	Since
Yong Gang Xing CHM	Chairman	50	2019-11-24
Yong Liu BRD	Director/Board Member	57	2021-05-16
Zeng He Dong CHM	Chairman	60	2023-07-13

	2023	2024
Net sales	12.07B 1.74B 1.47B 1.35B 1.28B 2.37B 158B 2.48B 15.68B 6.21B 75.86B 6.52B 6.39B 273B	10.94B 1.58B 1.33B 1.22B 1.16B 2.15B 143B 2.25B 14.21B 5.63B 68.75B 5.91B 5.79B 247B
Net income	692M 99.71M 84.4M 77.36M 73.27M 136M 9.03B 142M 899M 356M 4.35B 374M 366M 15.65B	1.08B 156M 132M 121M 115M 213M 14.15B 223M 1.41B 557M 6.81B 586M 574M 24.52B
Net Debt	-4.83B -696M -589M -540M -511M -949M -63.04B -993M -6.27B -2.48B -30.35B -2.61B -2.56B -109B	-6.51B -937M -794M -727M -689M -1.28B -84.93B -1.34B -8.45B -3.35B -40.89B -3.52B -3.44B -147B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+0.47%	+0.85%	-8.84%	+8.06%	2.06B
MERCK KGAA	-0.49%	-3.27%	-14.62%	-34.10%	62.57B
HALOZYME THERAPEUTICS, INC.	+3.58%	+13.28%	+40.20%	+56.69%	9.22B
KYOWA KIRIN CO., LTD.	+1.37%	-4.07%	+7.25%	-16.58%	7.9B
SK BIOPHARMACEUTICALS CO., LTD.	-2.69%	-8.05%	-14.57%	+51.96%	5.96B
YUHAN CORPORATION	-2.42%	-2.96%	-23.73%	+108.80%	5.45B
INDIVIOR PHARMACEUTICALS, INC.	-0.26%	-2.88%	+222.63%	+41.52%	4.3B
MEZZION PHARMA CO.,LTD.	-6.59%	-19.37%	+373.59%	+879.56%	3.09B
BETTA PHARMACEUTICALS CO., LTD.	-0.61%	+0.28%	-20.18%	-25.32%	2.88B
SUPERNUS PHARMACEUTICALS, INC.	+4.62%	+7.25%	+32.95%	+26.75%	2.83B
Average	-0.63%	-0.54%	+59.47%	+109.74%	10.63B
Weighted average by Cap.	-0.52%	-1.96%	+13.40%	+19.51%